Tetrodotoxin is under clinical development by WEX Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tetrodotoxin’s likelihood of approval (LoA) and phase transition for Low Back Pain took place on 07 Jan 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tetrodotoxin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tetrodotoxin overview

Tetrodotoxin (TTX, Tectin) is under development for the treatment of cancer related pain, chemotherapy-induced peripheral neuropathy, osteoarthritis, lower back pain and painful diabetic neuropathy. The drug candidate is administered through subcutaneous and intramuscular routes. Tetrodotoxin (TTX) is a non-peptide neurotoxin derived from the puffer fish and targets Nav1.7 voltage-gated sodium channels. It is developed based on the Tetrodotoxin (TTX) technology platform.

WEX Pharmaceuticals overview

WEX Pharmaceuticals (WEX), a subsidiary of CK Life Sciences Int’l, (Holdings) Inc, is a clinical stage biotechnology company. It focuses on the discovery, development, manufacture and commercialization of drugs for pain management. The company is developing a new class of non-opioid analgesics by utilizing its proprietary platform technology TTX (Tetrodotoxin or TTX). TTX is a non-peptide neurotoxin, non-addictive alternative to opioids, and a sodium channel blocker. WEX’s clinical candidates include TEC-006, and TTX-CINP-201, which are being studied for the treatment of moderate to severe cancer related pain and neuropathic pain caused by chemotherapy. WEX is headquartered in Vancouver, British Columbia, Canada.

Quick View Tetrodotoxin LOA Data

Report Segments
  • Innovator
Drug Name
  • Tetrodotoxin
Administration Pathway
  • Intramuscular
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Toxicology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.